A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas
A051902 is open to accrual to the Randomized Phase II Safety check portion of the study, effective September 18. 2023.
A051902 accrual to older patient cohort (age >60) is temporarily suspended effective June 26, 2024.
